Skip to main content
Oncodesign Precision Medicine S.A logo

Oncodesign Precision Medicine S.A — Investor Relations & Filings

Ticker · ALOPM ISIN · FR001400CM63 LEI · 969500ZDX1IY47LDL876 Euronext Access Plus Manufacturing
Open in API
Filings indexed 86 across all filing types
Latest filing 2024-10-22 Earnings Release
Country FR France
Listing Euronext Access Plus ALOPM

About Oncodesign Precision Medicine S.A

https://www.oncodesign.com/

Oncodesign Precision Medicine (OPM) is a biopharmaceutical company specializing in precision medicine. The company's mission is to develop and provide innovative therapeutic and diagnostic solutions to address therapeutic resistance and metastasis in cancer. OPM focuses on creating value through a patient-centric and translational approach, collaborating with clinicians, service providers, and experts. Its core activities are centered on discovering new treatments for resistant and metastatic cancers, aiming to identify the most effective therapeutic pathways for patients.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Earnings Release Classification · 1% confidence The document is a press release dated October 22, 2024, announcing the final results of a Phase 1 clinical study for a drug candidate (OPM-101). It details safety data, pharmacokinetics/pharmacodynamics (PK/PD), and outlines plans for the next clinical trial phase (Phase 1b/2a) to be filed in Q4 2024. This content—a detailed update on clinical trial progress, safety findings, and future development plans, issued via a press release—is characteristic of an Earnings Release (ER) or a general announcement related to operational/clinical progress. Since it is not a full annual report (10-K), a formal audit report (AR), or a transcript (CT), and it focuses on reporting recent results rather than just announcing the *publication* of a report (RPA), the most fitting category is Earnings Release (ER), as clinical trial results announcements often serve the function of periodic financial/operational updates for investors, similar to an earnings report, especially when they include forward-looking statements about future filings. Given the context of a biopharma company reporting clinical trial outcomes, ER is the best fit among the provided options for a substantive operational update. Q4 2024
2024-10-22 English
Informations privilégiées / Autres communiqués
Earnings Release Classification · 1% confidence The document is a press release dated October 22, 2024, detailing the final results of a Phase 1 clinical study for the drug candidate OPM-101. It discusses safety, pharmacokinetics (PK), and pharmacodynamics (PD) data from a trial involving healthy volunteers. Crucially, it announces the plan to submit a protocol for a Phase 1b/2a clinical trial in Q4 2024. This content—a detailed update on clinical trial results and future development plans, presented as a formal announcement—is characteristic of an Earnings Release (ER) or a general corporate/investor update. Since it focuses heavily on clinical trial results and future development milestones rather than just quarterly financial figures (which would suggest an IR or MRQ), and it is a formal announcement of results, it aligns best with an Earnings Release (ER) which often includes operational and clinical highlights, or potentially an Investor Presentation (IP) if it were structured as slides, but as a press release detailing results, ER is the closest fit among the options for a major operational update. Given the focus on clinical trial results and the announcement of the next trial phase, it functions as a significant operational update, often bundled with earnings announcements or released separately as a major news event. Since it is not a full financial report (10-K/IR) or a presentation (IP), and it is a release of key findings, ER is the most appropriate classification for a major operational/clinical milestone announcement. Q4 2024
2024-10-22 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from Oncodesign Precision Medicine (OPM) announcing the presentation of a scientific poster (data on OPM-101) at the UEG Week 2024 congress. It details the content of the presentation (safety, PK/PD data from Phase 1 trial) and provides context about the company's pipeline and technology platforms. This type of announcement, focusing on scientific data presentation at a medical conference, is typically classified as an Investor Presentation (IP) or sometimes a Regulatory Filing (RNS) if it were a mandatory disclosure. However, given the detailed nature of the scientific update and the context of presenting clinical trial data to investors/the public, 'Investor Presentation' (IP) is the most fitting category, as these announcements often accompany or summarize investor-facing materials, even if the primary event is a conference presentation. It is not a formal regulatory report (10-K, IR, ER) nor a simple announcement of a report release (RPA). Since it details clinical trial progress and scientific findings intended for investors, IP is appropriate.
2024-10-15 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release announcing that OPM presented scientific data (safety, PK/PD) on its drug candidate OPM-101 at the UEG Week 2024 conference. It details the poster presentation, the presenters, and provides company updates. This type of announcement, which communicates clinical trial results or scientific findings presented at a conference, is typically classified as an Earnings Release (ER) if it were quarterly results, or more generally, a Regulatory Filing (RNS) if it doesn't fit a more specific category like ER or CT. Since it is not a full financial report (10-K, IR), a transcript (CT), or a formal regulatory filing like a DIRS or DIV, and it is an announcement of scientific data presentation, it fits best under the general Regulatory Filings (RNS) category, as it is an announcement of corporate/clinical progress. Given the context of clinical trial updates being announced via press release, RNS is the most appropriate general category when specific clinical update codes are unavailable. However, since it is announcing the presentation of clinical data, which often accompanies or precedes an ER, and it is a formal announcement, RNS is the safest general classification.
2024-10-15 English
Rapports financiers et d'audit semestriels/examens réduits / Rapport financier semestriel
Audit Report / Information Classification · 1% confidence The document is titled 'Rapport de gestion Exercice clos le 30 juin 2024' (Management Report for the fiscal year ended June 30, 2024) and contains a detailed 'Sommaire' (Table of Contents) listing sections like 'Rapport de gestion' and financial tables for the '1er semestre 2024' (First half of 2024). It includes an attestation from the legal entity regarding the management report and financial statements, and provides extensive operational and financial details typical of a comprehensive periodic report. Although it covers the first half of the year (suggesting an Interim Report, IR), the overall structure, the inclusion of the 'Rapport de gestion' for the fiscal year end date (June 30), and the comprehensive nature strongly suggest this is the full annual report or a very detailed interim report that functions similarly to an annual report in structure, but the date points to a half-year review. However, the key indicator is the presence of the 'Rapport de gestion' for the fiscal year ended June 30, 2024, combined with the financial details for the first half (S1'24). Since the document explicitly covers the 'Exercice clos le 30 juin 2024' (Fiscal Year ended June 30, 2024), it aligns best with the Annual Report (10-K) structure, even if the detailed financials shown are only for the interim period, or it could be a very detailed Interim Report (IR). Given the explicit mention of 'Rapport de gestion' for the fiscal year end, and the comprehensive nature, 10-K is a strong candidate, but 'IR' (Interim Report) is also plausible for a half-year review. Since the document explicitly states 'Rapport de gestion Exercice clos le 30 juin 2024' and includes an audit attestation, it is most likely the Annual Report (10-K) or the associated Annual Report filing, even if the text snippet focuses on H1 results. If it were strictly a half-year report, it would typically be labeled as such without referencing the full fiscal year end in the main title. Given the context of a comprehensive report covering the fiscal year end, 10-K is the most appropriate classification for a full annual filing. H1 2024
2024-09-30 French
Informations privilégiées / Autres communiqués
Earnings Release Classification · 1% confidence The document explicitly announces the financial results for the first half of 2024 ("OPM annonce ses résultats du premier semestre 2024"). It contains detailed financial tables (Compte de résultat, Dépenses de R&D) and management commentary on performance, clinical pipeline updates (OPM-101, OPM-201), and cash position as of June 30, 2024. This structure is characteristic of a comprehensive periodic financial report covering a period shorter than a year. The final section mentions the 'rapport financier semestriel 2024' will be available later, but the content provided is the actual release of those results, making it an Interim/Quarterly Report (IR). It is not just an Earnings Release (ER) because it includes detailed financial statements and extensive operational review, nor is it a 10-K (Annual Report). H1 2024
2024-09-25 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.